Home > Boards > US OTC > Medical - Healthcare > InVivo Therapeutics Holdings Corp (NVIV)

Thanks Lazed. With the recent offering

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BesaoT35 Member Profile
Member Level 
Followed By 2
Posts 460
Boards Moderated 0
Alias Born 07/08/13
160x600 placeholder
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering Business Wire - 10/26/2020 4:15:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/26/2020 6:03:09 AM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 10/26/2020 6:02:10 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/23/2020 4:39:28 PM
InVivo Therapeutics Announces Pricing of $15.0 Million Public Offering Business Wire - 10/22/2020 9:15:00 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 10/7/2020 6:01:32 AM
InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference Business Wire - 9/11/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/11/2020 4:15:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2020 4:34:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2020 6:37:34 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/22/2020 6:04:21 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/9/2020 4:31:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2020 4:06:18 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/5/2020 6:01:40 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/4/2020 4:35:19 PM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 5/22/2020 5:26:10 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2020 4:07:21 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/28/2020 4:15:49 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 5:05:10 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 4:15:10 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/24/2020 11:19:24 AM
InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Business Wire - 4/17/2020 12:19:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/17/2020 6:01:44 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/16/2020 5:20:33 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 4/16/2020 11:30:13 AM
BesaoT35 Member Level  Tuesday, 03/17/20 10:09:26 PM
Re: None
Post # of 6167 
Thanks Lazed. With the recent offering I think there is less than 3.5 million shares outstanding. At $1.27 NVIV market cap is around $4.2 million. The NVIV company has now $7 million in cash. The expenses are mostly paying executive salaries and bonuses.

The first spinal surgery trials showed big promise but at the very end one patient died , but the death was totally unrelated to spinal surgery. The addition of nerve growth factors and/or stem cells could increase positive patient outcomes in the future. This should be a high priority area of research.

To start to have an effective treatment for paralysis in humans , where in the past there was no treatment at all, should be worth something, but the stock market sees little or no value in the Neural spinal scaffold (NSS) it seems.

How much more money will NVIV need to spend before completion of Inspire 2.0? Do the research medical centers bill NVIV for all the surgical costs and follow up care? Is it around 24 patients total?

Thanks.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences